Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 38 Carcinoma, Non-Small-Cell Lung 23 Stomach Neoplasms 19 Nasopharyngeal Carcinoma 19 Triple Negative Breast Neoplasms 18 Esophageal Squamous Cell Carcinoma 17 Esophageal Neoplasms 16 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 8 Sarcoma 6 Recurrence 6 Neoplasm Metastasis 6 Melanoma 6 Liver Neoplasms 6 Cholangiocarcinoma 6 Lung Neoplasms 5 Hodgkin Disease 5 Biliary Tract Neoplasms 5 Osteosarcoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Advanced Gastric Cancer 4 Rectal Neoplasms 3 Nasopharyngeal Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Urinary Bladder Neoplasms 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × camrelizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡